Chemistry:Cagrilintide

From HandWiki
Short description: Chemical compound
Cagrilintide
Clinical data
Other namesGLXC-26801
Identifiers
CAS Number
PubChem CID
UNII
Chemical and physical data
3D model (JSmol)

Cagrilintide is a long-acting analogue of amylin. It is being tested to treat obesity and type 2 diabetes by itself and in combination with semaglutide as cagrilintide/semaglutide.[1][2][3][4][5][6]

References

  1. Larsen, Anna T.; Sonne, Nina; Mohamed, Khaled Elhady; Bredtoft, Emma-Marie; Andersen, Frederik; Karsdal, Morten A.; Henriksen, Kim (1 June 2022). "823-P: The Long-Acting Dual Amylin and Calcitonin Receptor Agonist KBP Has Increased Efficacy on Weight Loss and Glucose Control Compared with Cagrilintide in Obese and Diabetic Rats". Diabetes 71 (Supplement_1). doi:10.2337/db22-823-P. https://diabetesjournals.org/diabetes/article/71/Supplement_1/823-P/146339. 
  2. Lau, David C W; Erichsen, Lars; Francisco, Ann Marie; Satylganova, Altynai; le Roux, Carel W; McGowan, Barbara; Pedersen, Sue D; Pietiläinen, Kirsi H et al. (December 2021). "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial" (in en). The Lancet 398 (10317): 2160–2172. doi:10.1016/S0140-6736(21)01751-7. PMID 34798060. https://discovery.ucl.ac.uk/id/eprint/10155031/. 
  3. Kruse, Thomas; Hansen, Jakob Lerche; Dahl, Kirsten; Schäffer, Lauge; Sensfuss, Ulrich; Poulsen, Christian; Schlein, Morten; Hansen, Ann Maria Kruse et al. (12 August 2021). "Development of Cagrilintide, a Long-Acting Amylin Analogue" (in en). Journal of Medicinal Chemistry 64 (15): 11183–11194. doi:10.1021/acs.jmedchem.1c00565. ISSN 0022-2623. PMID 34288673. https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00565. 
  4. Frias, Juan P; Deenadayalan, Srikanth; Erichsen, Lars; Knop, Filip K; Lingvay, Ildiko; Macura, Stanislava; Mathieu, Chantal; Pedersen, Sue D et al. (August 2023). "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial" (in en). The Lancet 402 (10403): 720–730. doi:10.1016/S0140-6736(23)01163-7. PMID 37364590. 
  5. D’Ascanio, Antonella M.; Mullally, Jamie A.; Frishman, William H. (8 March 2023). "Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity". Cardiology in Review Publish Ahead of Print. doi:10.1097/CRD.0000000000000513. PMID 36883831. 
  6. Larsen, A. T.; Mohamed, K. E.; Sonne, N.; Bredtoft, E.; Andersen, F.; Karsdal, MA; Henriksen, K. (1 December 2022). "Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models". Biomedicine & Pharmacotherapy 156: 113842. doi:10.1016/j.biopha.2022.113842. ISSN 0753-3322. PMID 36242844. https://www.sciencedirect.com/science/article/pii/S0753332222012318.